Frequency Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 08, 2022 at 04:05 pm EST
Share
Frequency Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported net loss was USD 19.55 million compared to USD 25.16 million a year ago. Basic loss per share from continuing operations was USD 0.55 compared to USD 0.73 a year ago.
For the nine months, net loss was USD 64.22 million compared to USD 63.19 million a year ago. Basic loss per share from continuing operations was USD 1.83 compared to USD 1.84 a year ago.
Korro Bio, Inc. is a biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the bodyâs natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Its Oligonucleotide Promoted Editing of RNA (OPERA) is a foundational platform for RNA editing, which is designed to edit RNA in vivo by delivering an oligonucleotide guide that can target specific RNA sequences. OPERA co-opts the cellâs natural process with its synthetic oligo and catalyzes a single base change to modify protein sequence and function without the need to permanently modify oneâs genome. The Company's focus areas include the liver and central nervous system (CNS).
KORRO BIO, INC. 
